Pharnext to Present at 4th International Neurotech Investing and Partnering Conference
September 28 2017 - 10:45AM
Business Wire
Regulatory News:
Pharnext SA (FR00111911287 - ALPHA) (Paris:ALPHA),
a biopharmaceutical company pioneering a new approach to the
development of innovative drugs based on the combination and
repositioning of known drugs, today announced that company
management will present a corporate overview at the 4th
International Neurotech Investing and Partnering Conference.
The presentation will take place as follows:
- Date: Wednesday, October 4th,
2017
- Time: 4:00pm CEST
- Venue: Wyss Center in Geneva,
Switzerland
If you are interested in meeting the Pharnext management team
during this event, please send an email to Anne Hennecke at
anne.hennecke@mc-services.eu.
About PharnextPharnext is an advanced clinical-stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext has two lead products in clinical development.
PXT3003 is currently in an international Phase 3 trial for the
treatment of Charcot-Marie-Tooth disease type 1A and benefits from
orphan drug status in Europe and the United States. PXT864 has
generated positive Phase 2 results in Alzheimer’s disease. Pharnext
is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The
Company identifies and develops synergic combinations of
repositioned drugs at new optimal lower doses. These PLEODRUG™
offer several key advantages: efficacy, safety and intellectual
property including several product or composition of matter patents
already granted. The Company is supported by a world-class
scientific team.
The company Pharnext is listed on Euronext Growth Stock Exchange
in Paris (ISIN code: FR00111911287).For more information, visit
www.pharnext.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170928005903/en/
PharnextXavier Paoli, +33 (0)1 41 09 22 30Chief
Commercial Officercontact@pharnext.comorInvestor Relations
(Europe)MC Services AGAnne Hennecke, +49 211 529252
22anne.hennecke@mc-services.euorInvestor Relations
(U.S.)Stern Investor Relations, Inc.Matthew Shinseki, +1 212
362 1200matthew@sternir.comorFinancial Communication
(France)ActifinStéphane Ruiz, +33 (0)1 56 88 11
15sruiz@actifin.frorMedia Relations (Europe)ALIZE RPCaroline
CarmagnolMargaux Pronost+33 (0)1 44 54 36
64pharnext@alizerp.comorMedia Relations
(U.S.)RooneyPartnersMarion Janic+1 212 223
4017mjanic@rooneyco.com
Pharnext (EU:ALPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharnext (EU:ALPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024